Biochemical stabilization of glucagon at alkaline pH

Diabetes Technology and Therapeutics

Volumn 16, Issue 11, 2014, Pages 747-758

  Caputo, Nicholas ^a   Jackson, Melanie A ^b   Castle, Jessica R ^a,b   El Youssef, Joseph ^a,b   Bakhtiani, Parkash A ^a,b   Bergstrom, Colin P ^b   Carroll, Julie M ^c   Breen, Matthew E ^a   Leonard, Gerald L ^a   David, Larry L ^a   Roberts, Charles T ^b,c   Ward, W Kenneth ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ARGININE; BETA CYCLODEXTRIN; CURCUMIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXCIPIENT; GLUCAGON; POLYSORBATE 80; TRYPTOPHAN; BUFFER; ENZYME INHIBITOR; METHIONINE; POLYSORBATE;

AGING; ALKALINITY; ANIMAL CELL; ARTICLE; BIOASSAY; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DEAMINATION; DEGRADATION; FLUORESCENCE ANALYSIS; FLUORESCENCE SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; OPTICAL DENSITY; OXIDATION; PH; PROTEIN AGGREGATION; PROTEIN CONTENT; PROTEIN STABILITY; TRANSMISSION ELECTRON MICROSCOPY; YORKSHIRE PIG; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG STABILITY; HUMAN; INSULIN INFUSION; MEDICINAL CHEMISTRY; PIG; PRECIPITATION; SPECTROFLUOROMETRY;

ANIMALS; BUFFERS; CHEMICAL PRECIPITATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, LIQUID; CURCUMIN; DRUG STABILITY; ENZYME INHIBITORS; GLUCAGON; HUMANS; INSULIN INFUSION SYSTEMS; METHIONINE; POLYSORBATES; PROTEIN STABILITY; SPECTROMETRY, FLUORESCENCE; SWINE; TRYPTOPHAN;

EID: 84911930447     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2014.0047     Document Type: Article

References (43)

1. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003;284: E671-E678.
2. Cryer PE: Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012;153:1039-1048.
3. El-Khatib FH, Jiang J, Gerrity RG, Damiano ER: Pharmacodynamics and stability of subcutaneously infused glucagon in a type 1 diabetic swine model in vivo. Diabetes Technol Ther 2007;9:135-144.
4. Ward WK, Engle J, Duman HM, Bergstrom CP, Kim SF, Federiuk IF: The benefit of subcutaneous glucagon during closed-loop glycemic control in rats with type 1 diabetes. IEEE Sensors J 2008;8:89-96.
5. Castle JR, Engle JM, El Youssef J, et al.: Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282-1287.
6. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER: A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27ra.
7. Haidar A, Legault L, Dallaire M, et al.: Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. Can Med Assoc J 2013;185:297-305.
8. Pedersen JS: The nature of amyloid-like glucagon fibrils. J Diabetes Sci Technol 2010;4:1357-1367.
9. Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE: The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. J Mol Biol 2006;355:501-523.
10. Pedersen JS, Otzen DE: Amyloid - a state in many guises: survival of the fittest fibril fold. Protein Sci 2008;17:2-10.
11. Onoue S, Ohshima K, Debari K, et al.: Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res 2004;21:1274-1283.
12. Ward WK, Massoud RG, Szybala CJ, et al.: In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect. J Diabetes Sci Technol 2010;4:1311-1321.
13. Chabenne JR, DiMarchi MA, Gelfanov VM, DiMarchi RD: Optimization of the native glucagon sequence for medicinal purposes. J Diabetes Sci Technol 2010;4:1322-1331.
14. Steiner SS, Li M, Hauser R, Pohl R: Stabilized glucagon formulation for bihormonal pump use. J Diabetes Sci Technol 2010;4:1332-1337.
15. Prestrelski S, Fang W-J, Carpenter JF, Kinzell J, inventors: Stable glucagon formulations for the treatment of hypoglycemia. U.S. Patent Application 20120046225. February 23, 2012.
16. Caputo N, Castle JR, Bergstrom CP, et al.: Mechanisms of glucagon degradation at alkaline pH. Peptides 2013;45:40-47.
17. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC: Multiple biological activities of curcumin: a short review. Life Sci 2006;78:2081-2087.
18. Anand P, Thomas SG, Kunnumakkara AB, et al.: Biological activities of curcumin and its analogues (congeners) made by man and Mother Nature. Biochem Pharmacol 2008;76:1590-1611.
19. Lopez-Lazaro M: Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 2008;52(Suppl 1):S103-S127.
20. Aggarwal BB, Sung B: Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009;30:85-94.
21. Gupta SC, Prasad S, Kim JH, et al.: Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 2011;28:1937-1955.
22. Gupta SC, Patchva S, Koh W, Aggarwal BB: Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012; 39:283-299.
23. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21:8370-8377.
24. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M: Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 2003; 87:172-181.
25. Ono K, Hasegawa K, Naiki H, Yamada M: Curcumin has potent anti-amyloidogenic effects for Alzheimer's b-amyloid fibrils in vitro. J Neurosci Res 2004;75:742-750.
26. Yang F, Lim GP, Begum AN, et al.: Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005; 280:5892-5901.
27. Porat Y, Abramowitz A, Gazit E: Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 2006;67:27-37.
28. Mishra S, Palanivelu K: The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann Indian Acad Neurol 2008;11:13-19.
29. Ahmad B, Lapidus LJ: Curcumin prevents aggregation in alpha-synuclein by increasing reconfiguration rate. J Biol Chem 2012;287:9193-9199.
30. Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK: Curcumin modulates alpha-synuclein aggregation and toxicity. ACS Chem Neurosci 2013;4:393-407.
31. Kurien BT, Singh A, Matsumoto H, Scofield RH: Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 2007;5:567-576.
32. Nilsson MR: Techniques to study amyloid fibril formation in vitro. Methods 2004;34:151-160.
33. Hudson SA, Ecroyd H, Kee TW, Carver JA: The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J 2009;276:5960-5972.
34. Noormagi A, Primar K, Tougu V, Palumaa P: Interference of low-molecular substances with the thioflavin-T fluorescence assay of amyloid fibrils. J Pept Sci 2012;18:59-64.
35. Zaccolo M, De Giorgi F, Cho CY, et al.: A genetically encoded, fluorescent indicator for cyclic AMP in living cells. Nat Cell Biol 2000;2:25-29.
36. Jackson MA, Caputo N, Castle JR, David LL, Roberts CT Jr, Ward WK: Stable liquid glucagon formulations for rescue treatment and bi-hormonal closed-loop pancreas. Curr Diabetes Rep 2012;12:705-710.
37. Leung MH, Kee TW: Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen. Langmuir 2009;25:5773-5777.
38. Wang YJ, Pan MH, Cheng AL, et al.: Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997;15:1867-1876.
39. Pedersen JS, Dikov D, Otzen DE: N- and C-terminal hydrophobic patches are involved in fibrillation of glucagon. Biochemistry 2006;45:14503-14512.
40. Reinke AA, Gestwicki JE: Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 2007;70:206-215.
41. Maji SK, Perrin MH, Sawaya MR, et al.: Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 2009;325:328-332.
42. Amundsen I, Oiestad AM, Ekeberg D, Kristoffersen L: Quantitative determination of fifteen basic pharmaceuticals in ante- and post-mortem whole blood by high pH mobile phase reversed phase ultra high performance liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2013;927:112-123.
43. Ward WK, Castle JR, Branigan DL, Massoud RG, El Youssef J: Discomfort from an alkaline formulation delivered subcutaneously in humans: albumin at pH 7 versus pH 10. Clin Drug Investig 2012;32:433-438.